Loading [MathJax]/jax/output/SVG/jax.js
Review Special Issues

Harnessing artificial intelligence for enhanced nanoparticle design in precision oncology

  • Received: 19 October 2024 Revised: 15 November 2024 Accepted: 29 November 2024 Published: 13 December 2024
  • The integration of artificial intelligence (AI) with nanoparticle technology represents a transformative approach in precision oncology, particularly in the development of targeted anticancer drug delivery systems. In our study, we found out that the application of AI in the field of drug delivery enhances the value of nanoparticles in increasing the efficiency of drug delivery and decreasing side effects from specifically targeted mechanisms. Moreover, we considered urgent issues that exist in present-day nanoparticle fabrication such as scalability and regulatory issues and suggest AI solutions that would help overcome these issues. In the same manner, we focused on the utilization of AI in enhancing patient-centered treatment through the establishment of drug delivery systems that will complement the genetic and molecular makeup of patients. Additionally, we present evidence suggesting that AI-designed nanoparticles have the potential to be environmentally sustainable alternatives in cancer therapy. AI is presented as capable of creating synergies with bioengineering methods like CRISPR or gene therapy and able to show potential directions for enhancing the efficiency of nanoparticle-based cancer therapies. In implementing these findings, we systematically discuss and highlight ongoing work and potential development trends in AI-aided nanoparticle research, asserting that it has the potential to greatly enhance oncology therapy.

    Citation: Mujibullah Sheikh, Pranita S. Jirvankar. Harnessing artificial intelligence for enhanced nanoparticle design in precision oncology[J]. AIMS Bioengineering, 2024, 11(4): 574-597. doi: 10.3934/bioeng.2024026

    Related Papers:

    [1] Gültekin Tınaztepe, Sevda Sezer, Zeynep Eken, Sinem Sezer Evcan . The Ostrowski inequality for $ s $-convex functions in the third sense. AIMS Mathematics, 2022, 7(4): 5605-5615. doi: 10.3934/math.2022310
    [2] Serap Özcan, Saad Ihsan Butt, Sanja Tipurić-Spužević, Bandar Bin Mohsin . Construction of new fractional inequalities via generalized $ n $-fractional polynomial $ s $-type convexity. AIMS Mathematics, 2024, 9(9): 23924-23944. doi: 10.3934/math.20241163
    [3] Muhammad Samraiz, Kanwal Saeed, Saima Naheed, Gauhar Rahman, Kamsing Nonlaopon . On inequalities of Hermite-Hadamard type via $ n $-polynomial exponential type $ s $-convex functions. AIMS Mathematics, 2022, 7(8): 14282-14298. doi: 10.3934/math.2022787
    [4] Tekin Toplu, Mahir Kadakal, İmdat İşcan . On n-Polynomial convexity and some related inequalities. AIMS Mathematics, 2020, 5(2): 1304-1318. doi: 10.3934/math.2020089
    [5] Haoliang Fu, Muhammad Shoaib Saleem, Waqas Nazeer, Mamoona Ghafoor, Peigen Li . On Hermite-Hadamard type inequalities for $ n $-polynomial convex stochastic processes. AIMS Mathematics, 2021, 6(6): 6322-6339. doi: 10.3934/math.2021371
    [6] Naila Mehreen, Matloob Anwar . Ostrowski type inequalities via some exponentially convex functions with applications. AIMS Mathematics, 2020, 5(2): 1476-1483. doi: 10.3934/math.2020101
    [7] Attazar Bakht, Matloob Anwar . Ostrowski and Hermite-Hadamard type inequalities via $ (\alpha-s) $ exponential type convex functions with applications. AIMS Mathematics, 2024, 9(10): 28130-28149. doi: 10.3934/math.20241364
    [8] Humaira Kalsoom, Muhammad Idrees, Artion Kashuri, Muhammad Uzair Awan, Yu-Ming Chu . Some New $(p_1p_2,q_1q_2)$-Estimates of Ostrowski-type integral inequalities via n-polynomials s-type convexity. AIMS Mathematics, 2020, 5(6): 7122-7144. doi: 10.3934/math.2020456
    [9] Anjum Mustafa Khan Abbasi, Matloob Anwar . Ostrowski type inequalities for exponentially s-convex functions on time scale. AIMS Mathematics, 2022, 7(3): 4700-4710. doi: 10.3934/math.2022261
    [10] Wei Gao, Artion Kashuri, Saad Ihsan Butt, Muhammad Tariq, Adnan Aslam, Muhammad Nadeem . New inequalities via n-polynomial harmonically exponential type convex functions. AIMS Mathematics, 2020, 5(6): 6856-6873. doi: 10.3934/math.2020440
  • The integration of artificial intelligence (AI) with nanoparticle technology represents a transformative approach in precision oncology, particularly in the development of targeted anticancer drug delivery systems. In our study, we found out that the application of AI in the field of drug delivery enhances the value of nanoparticles in increasing the efficiency of drug delivery and decreasing side effects from specifically targeted mechanisms. Moreover, we considered urgent issues that exist in present-day nanoparticle fabrication such as scalability and regulatory issues and suggest AI solutions that would help overcome these issues. In the same manner, we focused on the utilization of AI in enhancing patient-centered treatment through the establishment of drug delivery systems that will complement the genetic and molecular makeup of patients. Additionally, we present evidence suggesting that AI-designed nanoparticles have the potential to be environmentally sustainable alternatives in cancer therapy. AI is presented as capable of creating synergies with bioengineering methods like CRISPR or gene therapy and able to show potential directions for enhancing the efficiency of nanoparticle-based cancer therapies. In implementing these findings, we systematically discuss and highlight ongoing work and potential development trends in AI-aided nanoparticle research, asserting that it has the potential to greatly enhance oncology therapy.



    These days, the investigation on convexity theory is considered as a unique symbol in the study of the theoretical conduct of mathematical inequalities. As of late, a few articles have been published with a special reference to integral inequalities for convex functions. Specifically, much consideration has been given to the theoretical investigations of inequalities on various kinds of convex functions, for example, s-type convex functions, Harmonic convex functions, tgs-convex functions, Exponential type convex functions, GA-convex functions, (α,m)-convex functions, MT-convex functions, Hyperbolic convex functions, Trigonometrically convex functions, Exponential s-type convex functions, and so on. Many researchers have worked on the above mentioned convexities in different directions with some innovative applications. The most interesting aspect of these variants of convex functions is that each definition is generalization of other one for some specific values. For example, if we choose s=1 in exponentially s-convex function, it simply reduces to exponentially convex function. For the attention of the readers, see the references [1,2,3,4,5,6,7,8].

    In 1938, Ostrowski introduced the following useful and interesting integral inequality (see [9], page 468).

    Let φ:JRR be a differentiable mapping on Jo, the interior of the interval J, such that φL[α1,α2], where α1,α2J with α2>α1. If |φ(z)|K, for all z[α1,α2], then the following inequality:

    |φ(z)1α2α1α2α1φ(u)du|K(α2α1)[14+(zα1+α22)2(α2α1)2] (1.1)

    holds. The above inequality (1.1), in literature is known as the well known Ostrowski inequality. For some detailed knowledge about the recent researches on this inequality and related generalizations and extensions, see ([10,11,12,13,14,15,16]). This inequality yields an upper bound for the approximation of the integral average 1α2α1α2α1φ(u)du by the value of φ(u) at the point u[α1,α2].

    Since the time it is established, broad research history on establishing numerous generalizations of Ostrowski type inequalities have been directed. Most of the earlier and current investigations use different properties of the function and additionally use convexity and bounded variation. The posterity of Ostrowski type inequalities has a great role in the numerical integration theory as utilized by numerous mathematicians. They furnish the numerical integration field with a huge class of quadrature and cubature rules as well.

    In assorted and rival research, inequalities have a ton of utilizations in measure theory, mathematical finance, statistical problems, probability, and numerical quadrature formulas. Meng et al. in [17,18] applied the convex model for optimization via probabilistic approach. Brown in his article[19], explained the relationship between inequalities and measure theory. Numerous broadly known outcomes about inequalities can be acquired utilizing the properties of convex functions. In 1994, for the first-time Hudzik and Maligranda [20] presented the class of s-convex functions in the second sense. Further towards this path, Dragomir and Fitzpatrick [21] put endeavors and set up new fundamental inequalities by means of s-convex functions. In 2019, İşcan [22] developed some new Hermite-Hadamard type inequalities for s-convex functions with the help of notable inequalities like improved power-mean Integral inequality and Hölder-İscan integral inequality.

    In the frame of simple calculus, we explore and attain the novel refinements of Ostrowski type inequalities. To the best of our knowledge, a comprehensive investigation of newly introduced definition, namely n-polynomial exponentially s-convex function in the present paper is new. Recently, it is seen that many scientists are interested in big data analysis, deep learning and information theory utilizing the concept of exponentially convex functions.

    Motivated by the ongoing research and literature, the present paper is structured in the following way, first in Section 2, we will give some necessary known definitions and literature. Second in Section 3, we will explore the concept of n-polynomial exponentially s-convex functions. In addition, some algebraic properties and examples for the newly introduced definition are elaborated. In Section 4, we attain the new sort of Hermite-Hadamrd type inequality. Further, in Section 5, we investigate some refinements of the Ostrowski type inequality and some special cases. Finally, in the next section we present some applications to special means and a conclusion.

    In this section, we recall some known concepts.

    Definition 2.1. [23] Let φ:IR be a real valued function. A function φ is said to be convex, if

    φ(χα1+(1χ)α2)χφ(α1)+(1χ)φ(α2), (2.1)

    holds for all α1,α2I and χ[0,1].

    The Hermite-Hadamard inequality states that, if a mapping φ:JRR is convex on J for α1,α2J and α2>α1, then

    φ(α1+α22)1α2α1α2α1φ(χ)dχφ(α1)+φ(α2)2. (2.2)

    Interested readers can refer to [21,24].

    Definition 2.2. [25] A function φ:[0,+)R is said to be s-convex in the second sense for a real number s(0,1] or φ belongs to the class of K2s, if

    φ(χα1+(1χ)α2)χsφ(α1)+(1χ)sφ(α2) (2.3)

    holds for all α1,α2[0,+) and χ[0,1].

    Breckner in his article [26] introduced, s-convex functions. Hudzik in his paper [20] presented a few properties and connections with s-convexity in the first sense. Usually, when we put s=1 for s-convexity, it reduces to the classical convexity. In [21], Dragomir et al. proved a generalized Hadamard's inequality, which holds for s-convex functions in the second sense.

    Recently, many researchers investigated about the importance and development of the theory of exponentially convex functions. In 2020, Kadakal et al.[27], investigated a new class of exponential convexity, which is stated as follows:

    Definition 2.3. [27] A non-negative real-valued function φ:JRR is known to be an exponential convex function if the following inequality holds:

    φ(χα1+(1χ)α2) (eχ1)φ(α1)+(e(1χ)1)φ(α2). (2.4)

    Definition 2.4. [28] A non-negative real-valued function φ:JR is called n-polynomial convex, if

    φ(χα1+(1χ)α2)1nni=1[1(1χ)i]φ(α1)+1nni=1[1χi]φ(α2), (2.5)

    holds for every α1,α2J, χ[0,1], s[0,1] and nN.

    Employing the above concepts Iscan et al. in [27,28] proved the following results respectively:

    Theorem 2.5. Let φ:[α1,α2]R be an exponential type convex function. If α1<α2 and φL[α1,α2], then the following Hermite-Hadamard type inequality holds:

    12(e121)φ(α1+α22)1α2α1α2α1φ(u) du(e2)[φ(α1)+φ(α2)]. (2.6)

    Theorem 2.6. Let φ:[α1,α2]R be an n polynomial convex function. If α1<α2 and φL[α1,α2], then the following Hermite-Hadamard type inequality holds:

    12(nn+2n1)φ(α1+α22)1α2α1α2α1φ(u)du(φ(α1)+φ(α2)n)ns=1ss+1. (2.7)

    In [30], the authors proved some refinements of Hermite-Hadamard inequality for exponential convex function. Qi et al. [31], presented Hermite-Hadamard inequality for exponential (α,(hm)) convex function. Recently, Naz et al. [32], used k-Hilfer Katugampola derivative to establish Ostrowski type inequality for n-polynomial P-convex function. For some recent developements on n-polynomial convexity interested readers can refer to [33,34] and the references cited therein.

    Next, due to afore-mentioned research activities, we are able and capable to introduce the generalized form of exponential type convexity, which is called an n-polynomial exponentially s-convex function. Further, we will try to discuss and explore its properties.

    Definition 3.1. Let nN and s[ln2.4,1]. Then the non-negative real-valued function φ:JRR is known to be an n-polynomial exponentially s-convex function if the following inequality holds:

    φ(χα1+(1χ)α2) 1nni=1(esχ1)iφ(α1)+1nni=1(es(1χ)1)iφ(α2). (3.1)

    We represent the class of all n-polynomial exponentially type convex functions on the interval J as POLEXPC(J) for each α1,α2J and χ[0,1].

    Remark 1. In above Definition 3.1, if n=s=1, then we get (2.4) given by İşcan in [27].

    Remark 2. The range of the exponentially s-convex functions for some fixed s[ln2.4,1] is [0,+).

    Lemma 3.2. For all χ[0,1] and for some fixed s[ln2.4,1] the following inequalities 1nni=1(esχ1)iχ and 1nni=1(es(1χ)1)i(1χ) hold.

    Proof. The proof is simple.

    Lemma 3.3. For all χ[0,1] and for some fixed s[ln2.4,1] the following inequalities 1nni=1(esχ1)iχs and 1nni=1(es(1χ)1)i(1χ)s hold.

    Proof. The proof is simple.

    From the above lemmas, it can be clearly seen that, the new class of n-polynomial exponentially convex function is very larger when compared to the known class of functions like convex, exponentially convex, s-convex and exponentially s-convex. This is an added advantage of the newly proposed Definition 3.1.

    Proposition 1. Every nonnegative convex function is an n-polynomial exponentially s-convex function for s[ln2.4,1].

    Proof. Applying Lemma 3.2 and s[ln2.4,1], we have

    φ(χα1+(1χ)α2)χφ(α1)+(1χ)φ(α2)1nni=1(esχ1)iφ(α1)+1nni=1(e(1χ)s1)iφ(α2).

    Proposition 2. Every nonnegative s-convex function is an n-polynomial exponentially s-convex function for s[ln2.4,1].

    Proof. Applying Lemma 3.3 and s[ln2.4,1], we have

    φ(χα1+(1χ)α2)χsφ(α1)+(1χ)sφ(α2)1nni=1(esχ1)iφ(α1)+1nni=1(e(1χ)s1)iφ(α2).

    Now, we will makes some examples in the support of the newly introduced function.

    Example 1. If φ(x)=ex,for all x>0 is a nonnegative convex function, from Proposition 1, it is also an n-polynomial exponentially s-convex function for s[ln2.4,1].

    Example 2. If φ(x)=c is a nonnegative convex function on R for any c0, from Proposition 1, it is also an n-polynomial exponentially s-convex function for s[ln2.4,1].

    Example 3. If φ(x)=1x, for all x>0 is a nonnegative convex function, from Proposition 1, it is also an n-polynomial exponentially s-convex function for s[ln2.4,1].

    Example 4. φ(x)=qs+qxsq+1, for s>1 is a nonnegative convex function. By using Proposition 1, it is also n-polynomial exponentially s-convex function for s[ln2.4,1].

    Example 5. The Great mathematician Dragomir clearly investigated and proved that in published article [21], the function φ(x)=xls, x>0 is s-convex function, for the all mentioned conditions s(0,1) and 1l1s. But, using Proposition 2, it is also an n-polynomial exponentially s-convex function for s[ln2.4,1].

    Theorem 3.4. Let ψ,φ:[α1,α2]R. If ψ and φ are n-polynomial exponentially s-convex functions and s[ln2.4,1] then

    (i) ψ+φ is an n-polynomial exponentially s-convex function.

    (ii) For nonnegative real number c, cψ is an n-polynomial exponentially s-convex function.

    Proof. (i) Let ψ and φ be n-polynomial exponentially s-convex functions, then

    (ψ+φ)[(χα1+(1χ)α2)]=ψ(χα1+(1χ)α2)+φ(χα1+(1χ)α2)1nni=1(esχ1)iψ(α1)+1nni=1(e(1χ)s1)iψ(α2)+1nni=1(esχ1)iφ(α1)+1nni=1(e(1χ)s1)iφ(α2)=1nni=1(esχ1)i[ψ(α1)+φ(α1)]+1nni=1(e(1χ)s1)i[ψ(α2)+φ(α2)]= 1nni=1(esχ1)i(ψ+φ)(α1)+1nni=1(e(1χ)s1)i(ψ+φ)(α2).

    (ii) Let ψ be an n-polynomial exponentially s-convex function, then

    (cψ)[(χα1+(1χ)α2)]=c[ψ(χα1+(1χ)α2)]c[1nni=1(esχ1)iψ(α1)+1nni=1(e(1χ)s1)iψ(α2)]=1nni=1(esχ1)icψ(α1)+1nni=1(e(1χ)s1)icψ(α2)= 1nni=1(esχ1)i(cψ)(α1)+1nni=1(e(1χ)s1)i(cψ)(α2).

    Remark 3. If we choose s=1 in Theorem 3.4, then we get Theorem 2.1 in [27].

    Theorem 3.5. Let φi:[α1,α2]R be an arbitrary family of n-polynomial exponentially s-convex functions for the same fixed s[ln2.4,1] and let φ(α)=supiφi(α). If P={α[α1,α2]:φ(α)<+}, then P is an interval and φ is an n-polynomial exponentially s-convex function on P.

    Proof. For all α1,α2P and χ[0,1], and for the same fixed numbers s[ln2.4,1], we have

    φ(χα1+(1φ)α2)=supiφi(χα1+(1χ)α2)supi[1nni=1(esχ1)iφi(α1)+1nni=1(e(1χ)s1)iφi(α2)]1nni=1(esχ1)isupiφi(α1)+1nni=1(e(1χ)s1)isupiφi(α2)=1nni=1(esχ1)iφ(α1)+1nni=1(e(1χ)s1)iφ(α2)<+.

    This shows that P is an interval.

    Theorem 3.6. If the function φ:[α1,α2]R is n-polynomial exponentially s-convex for some fixed s[ln2.4,1], then φ is bounded on [α1,α2].

    Proof. Let L=max{φ(α1),ψ(α2)} and x[α1,α2] be an arbitrary point. Then there exists χ[0,1] such that x=χα1+(1χ)α2. Thus, since esχes and e(1χ)ses for some fixed s[ln2.4,1], we have

    φ(x)=φ(χα1+(1χ)α2)1nni=1(esχ1)iφ(α1)+1nni=1(e(1χ)s1)iφ(α2)1nni=1(es1)iL+1nni=1(es1)iL=L1nni=1(es1)i=M.

    We have proved that φ is bounded above by M.

    Remark 4. If we choose n=s=1 in Theorem 3.6, then we get Theorem 2.4 in [27].

    In this section, we present one Hermite-Hadamard type inequality for the n-polynomial exponentially s-convex function.

    Theorem 4.1. Suppose s[ln2.4,1], α(0,1], α2>α1 and φ:J=[α1,α2]R is an n-polynomial exponentially s-convex function such that φL[α1,α2]. Then one has

    121nni=1(es21)iφ(α1+α22)1α2α1α2α1φ(u) du1nni=1(ess1s)i[φ(α1)+φ(α2)] . (4.1)

    Proof. Let z1,z2J. Then it follows from the n-polynomial exponentially s-convex function for φ on J that

    φ(z1+z22)  1nni=1(es21)i[φ(z1)+φ(z2)] (4.2)
    Suppose  z1=χα2+(1χ)α1     and   z2=χα1+(1χ)α2.

    Then (4.2) leads to

    φ(α1+α22)  1nni=1(es21)i[φ(χα2+(1χ)α1  )+φ(χα1+(1χ)α2)]. (4.3)

    Now, integrating both sides of the inequality (4.3) with respect to χ from 0 to 1, one has

    φ(α1+α22)  1nni=1(es21)i[10φ(χα2+(1χ)α1  )dχ+10φ(χα1+(1χ)α2) dχ].
    121nni=1(es21)iφ(α1+α22)1α2α1α2α1φ(u) du.

    This completes the proof of first part of inequality (4.1). Next, we prove the second part of inequality (4.1). Let χ[0,1]. Using the fact that φ is an n-polynomial exponentially s-convex function, we obtain

    φ(χα2+(1χ)α1  )1nni=1(esχ1)iφ(α2)+1nni=1(es(1χ)1)iφ(α1) (4.4)

    and

    φ(χα1+(1χ)α2  )1nni=1(esχ1)iφ(α1)+1nni=1(es(1χ)1)iφ(α2). (4.5)

    By adding the above inequalities, we obtain

    φ(χα2+(1χ)α1  )+φ(χα1+(1χ)α2  ) [φ(α1)+φ(α2)]{1nni=1(esχ1)i+1nni=1(es(1χ)1)i}. (4.6)

    Now, integrating both sides of the above inequality with respect to χ from 0 to 1, then making the change of variable, we obtain

    2α2α1α2α1φ(u) du [φ(α1)+φ(α2)]10{1nni=1(esχ1)i+1nni=1(es(1χ)1)i}dχ,

    which leads to the conclusion that

    2α2α1α2α1φ(u) du2nni=1(ess1s)i[φ(α1)+φ(α2)].

    The proof is completed.

    Remark 5. If we choose n=s=1, then Theorem 4.1 becomes to [Theorem 3.1, [27]].

    In this section, we present some enhancements of the Ostrowski type inequality for differentiable n-polynomial exponentially s-convex function. Here, we need the following lemma as given in [29].

    Lemma 5.1. Suppose φ:JRR is a differentiable mapping on Jo, where α1,α2J with α1<α2. If φL[α1,α2], then the following equality holds:

    φ(z)1α2α1α2α1φ(χ)dχ= (zα1)2α2α110χ φ(χz+(1χ)α1) dχ(α2z)2α2α110χ φ(χz+(1χ)α2) dχ, (5.1)

    for each z[α1,α2].

    Theorem 5.2. Suppose φ:JRR is a differentiable mapping on Jo, where α1,α2J with α1<α2. If |φ| is an n-polynomial exponentially s-convex function on [α1,α2] for some s[ln2.4,1], φL[α1,α2] and |φ(z)|K, for all z[α1,α2], then the following inequality holds:

    |φ(z)1α2α1α2α1φ(χ)dχ|K(α2α1)n[(zα1)2 {ni=1(2+2(s1)ess22s2)i+ni=1(2ess22s22s2)i}+ (α2z)2 {ni=1(2+2(s1)ess22s2)i+ni=1(2ess22s22s2)i} ], (5.2)

    for each z[α1,α2].

    Proof. From Lemma 5.1, the fact that |φ| is n-polynomial exponentially s-convex and |φ|K, we have

    |φ(z)1α2α1α2α1φ(χ)dχ| (zα1)2α2α110χ |φ(χz+(1χ)α1)| dχ+(α2z)2α2α110χ| φ(χz+(1χ)α2)| dχ (zα1)2α2α110χ {1nni=1(esχ1)i|φ(z)|+1nni=1(es(1χ)1)i|φ(α1)|} dχ+(α2z)2α2α110χ{1nni=1(esχ1)i|φ(z)|+1nni=1(es(1χ)1)i|φ(α2)|} dχ (zα1)2α2α1[|φ(z)|10χ 1nni=1(esχ1)i dχ+|φ(α1)|10χ 1nni=1(es(1χ)1)idχ] +(α2z)2α2α1[|φ(z)|10χ 1nni=1(esχ1)i dχ+|φ(α2)|10χ 1nni=1(es(1χ)1)idχ] K(zα1)2(α2α1)n{ni=1(2+2(s1)ess22s2)i+ni=1(2ess22s22s2)i}  +K(α2z)2(α2α1)n{ni=1(2+2(s1)ess22s2)i+ni=1(2ess22s22s2)i}=  K(α2α1)n[(zα1)2 {ni=1(2+2(s1)ess22s2)i+ni=1(2ess22s22s2)i} + (α2z)2 {ni=1(2+2(s1)ess22s2)i+ni=1(2ess22s22s2)i}].

    The proof is completed.

    Corollary 1. If we choose n=1 in Theorem 5.2, we obtain

    |φ(z)1α2α1α2α1φ(u)du| K(α2α1)[(zα1)2 {(2+2(s1)ess22s2)+(2ess22s22s2)} + (α2z)2 {(2+2(s1)ess22s2)+(2ess22s22s2)}].

    Corollary 2. Under the similar consideration in Theorem 5.2, by choosing s=1, we obtain

    |φ(z)1α2α1α2α1φ(u)du| Kn(α2α1)[(zα1)2 {ni=1(12)i+ni=1(2e52)i}+ (α2z)2 {ni=1(12)i+ni=1(2e52)i}].

    Also, we have

    1.If we choose z=α1+α22 in Corollary 2, then we have the following mid-point inequality:

    |φ(α1+α22)1α2α1α2α1φ(u) du| Kn (α2α1)2{ni=1(12)i+ni=1(2e52)i}.

    2.If we choose z=α1 in Corollary 2, then we have the following inequality:

    |φ(α1)1α2α1α2α1φ(u) du| Kn (α2α1){ni=1(12)i+ni=1(2e52)i}.

    3.If we choose z=α2 in Corollary 2, then we have the following inequality:

    |φ(α2)1α2α1α2α1φ(u) du| Kn (α2α1){ni=1(12)i+ni=1(2e52)i}.

    Theorem 5.3. Suppose φ:JRR is a differentiable mapping on Jo, where α1,α2J with α1<α2. If |φ|q is n-polynomial exponentially s-convex on [α1,α2] for some s[ln2.4,1], q>1, q1=1p1, φL[α1,α2] and |φ(z)|K, for all z[α1,α2], then the following inequality holds:

    |φ(z)1α2α1α2α1φ(χ)dχ|21qK(α2α1)qn(1p+1)1p[(zα1)2{ni=1(ess1s)i}1q+(α2z)2{ni=1(ess1s)i}1q], (5.3)

    for each z[α1,α2].

    Proof. From Lemma 5.1 and the famous Hölder's inequality, we have

    |φ(z)1α2α1α2α1φ(χ)dχ| (zα1)2α2α110χ |φ(χz+(1χ)α1)| dχ+(α2z)2α1α110χ| φ(χz+(1χ)α2)| dχ (zα1)2α2α1(10χpdχ)1p(10|φ(χz+(1χ)α1)|qdχ)1q+ (α2z)2α2α1(10χpdχ)1p(10|φ(χz+(1χ)α2)|qdχ)1q. (5.4)

    Since |φ|q is n-polynomial exponentially s-convex and |φ(z)|K, we obtain

    10|φ(χz+(1χ)α1)|qdχ= 10{1nni=1(esχ1)i|φ(z)|q+1nni=1(es(1χ)1)i|φ(α1)|q}dχ Kq 1nni=1(ess1s)i+Kq 1nni=1(ess1s)i 2Kq 1nni=1(ess1s)i (5.5)

    and

    10|φ(χz+(1χ)α2)|qdχ= 10{1nni=1(esχ1)i|φ(z)|q+1nni=1(es(1χ)1)i|φ(α2)|q}dχ Kq 1nni=1(ess1s)i+Kq 1nni=1(ess1s)i 2Kq 1nni=1(ess1s)i. (5.6)

    By connecting (5.5) and (5.6) with (5.4), we get (5.3). The proof is completed.

    Corollary 3. If we choose n=1 in Theorem 5.3, we obtain

    |φ(z)1α2α1α2α1φ(u)du|21qK(α2α1)(1p+1)1p[(zα1)2(ess1s)1q+(α2z)2(ess1s)1q].

    Corollary 4. Under the similar consideration in Theorem 5.3, by choosing s=1, we obtain

    |φ(x)1α2α1α2α1φ(u)du|21qKqn(α2α1)(1p+1)1p[(zα1)2{ni=1(e2)i}1q+(α2z)2{ni=1(e2)i}1q].

    Also we have

    1.If we choose z=α1+α22 in Corollary 4, then we have the following mid-point inequality:

    |φ(α1+α22)1α2α1α2α1φ(u) du| 21q1K(α2α1)qn(1p+1)1p{ni=1(e2)i}1q.

    2.If we choose z=α1 in Corollary 4, then we have the following inequality:

    |φ(α1)1α2α1α2α1φ(u) du| 21qKqn (α2α1)(1p+1)1p{ni=1(e2)i}1q.

    3.If we choose z=α2 in Corollary 4, then we have the following inequality:

    |φ(α2)1α2α1α2α1φ(u) du| 21qKqn (α2α1)(1p+1)1p{ni=1(e2)i}1q.

    Theorem 5.4. Suppose φ:JRR is a differentiable mapping on Jo, where α1,α2J with α1<α2. If |φ|q is n-polynomial exponentially s-convex on [α1,α2] for some s[ln2.4,1], q1, q1=1p1, φL[α1,α2] and |φ(z)|K, for all z[α1,α2], then the following inequality holds:

    |φ(z)1α2α1α2α1φ(χ)dχ| Kqn(α2α1)211q[(zα1)2 {ni=1(2+(2s2)ess22s2)i+ni=1(2ess22s22s2)i}1q+ (α2z)2 {ni=1(2+(2s2)ess22s2)i+ni=1(2ess22s22s2)i}1q], (5.7)

    for each z[α1,α2].

    Proof. From Lemma 5.1 and power mean inequality, we have

    |φ(z)1α2α1α2α1φ(χ)dχ| (zα1)2α2α110χ |φ(χz+(1χ)α1)| dχ+(α2z)2α2α110χ| φ(χz+(1χ)α2)| dχ (zα1)2α2α1(10χ dχ)11q(10χ|φ(χz+(1χ)α1)|qdχ)1q+ (α2z)2α2α1(10χ dχ)11q(10χ|φ(χz+(1χ)α2)|qdχ)1q. (5.8)

    Since |φ|q is n-polynomial exponentially s-convex and |φ(z)|K, we obtain

    10χ|φ(χz+(1χ)α1)|qdχ= 10χ{1nni=1(esχ1)i|φ(z)|q+1nni=1(es(1χ)1)i|φ(α1)|q}dχ Kq 1nni=1((2s2)ess2+22s2)i+Kq 1nni=1(2ess22s22s2)i (5.9)

    and

    10χ|φ(χz+(1χ)α2)|qdχ=10χ{1nni=1(esχ1)i|φ(z)|q+1nni=1(es(1χ)1)i|φ(α2)|q}dχKq1nni=1((2s2)ess2+22s2)i+Kq1nni=1(2ess22s22s2)i. (5.10)

    By connecting (5.9) and (5.10) with (5.8), we get (5.7). The proof is completed.

    Corollary 5. If we choose n=1 in Theorem 5.4, we obtain

    |φ(z)1α2α1α2α1φ(u)du| K(α2α1)211q[(zα1)2 {(2+(2s2)ess22s2)+(2ess22s22s2)}1q + (α2z)2 {(2+(2s2)ess22s2)+(2ess22s22s2)}1q].

    Corollary 6. Under the similar consideration in Theorem 5.4, by choosing s=1, we obtain

    |φ(z)1α2α1α2α1φ(u)du| Kqn(α2α1)211q[(zα1)2 {ni=1(12)i+ni=1(2e52)i}1q + (α2z)2 {ni=1(12)i+ni=1(2e52)i}1q ].

    We also have

    1.If we choose z=α1+α22 in Corollary 6, then we have the following mid-point inequality:

    |φ(α1+α22)1α2α1α2α1φ(u) du| K 2qn(α2α1)211q{ni=1(12)i+ni=1(2e52)i}1q.

    2.If we choose z=α1 in Corollary 6, then we have the following inequality:

    |φ(α1)1α2α1α2α1φ(u) du| K qn(α2α1)211q{ni=1(12)i+ni=1(2e52)i}1q.

    3.If we choose z=α2 in Corollary 6, then we have the following inequality:

    |φ(α2)1α2α1α2α1φ(u) du|K qn(α2α1)211q{ni=1(12)i+ni=1(2e52)i}1q.

    Theorem 5.5. Suppose φ:JRR is a differentiable mapping on Jo, where α1,α2J with α2>α1. If |φ|q is n-polynomial exponentially s-concave on [α1,α2], for some s[ln2.4,1], φL[α1,α2], p,q>1, q1+p1=1, then the following inequality holds:

    |φ(z)1α2α1α2α1φ(χ)dχ|1α2α1(1p+1)1p(121nni=1(es21)i)1q×{(zα1)2|φ(z+α12)|+(α2z)2|φ(z+α22)|}. (5.11)

    Proof. Suppose p>1, by Lemma 5.1 and using the Hölder inequality, we obtain

    |φ(z)1α2α1α2α1φ(χ)dχ|(zα1)2α2α1(10χpdχ)1p (10|φ(χz+(1χ)α1)|qdχ)1q+(α2z)2α2α1(10χpdχ)1p (10|φ(χz+(1χ)α2)|qdχ)1q (5.12)

    |φ|q is n-polynomial exponentially s-concave, so using the left hand side of (4.1) inequality, we obtain

    10|φ(χz+(1χ)α1)|qdχ (121nni=1(es21)i)|φ(z+α12)|q (5.13)

    and

    10|φ(χz+(1χ)α2)|qdχ (121nni=1(es21)i)|φ(z+α22)|q. (5.14)

    By connecting the (5.13), (5.14) with (5.12), we get (5.11). The proof is completed.

    Corollary 7. If we choose n=1 in Theorem 5.5, we obtain

    |φ(z)1α2α1α2α1φ(u)du| 1α2α1(1p+1)1p(12(es21))1q{(zα1)2|φ(z+α12)|+(α2z)2|φ(z+α22)|}.

    Corollary 8. Under the similar consideration in Theorem 5.5, by choosing s=1, we obtain

    |φ(z)1α2α1α2α1φ(u)du| 1α2α1(1p+1)1p(121nni=1(es21)i)1q{(zα1)2|φ(z+α12)|+(α2z)2|φ(z+α22)|}.

    Consider the following special means for different positive real numbers α1,α2 and α1<α2 as follows:

    1.The Arithmetic mean:

    A(α1,α2)=α1+α22.

    2.The Harmonic mean:

    H(α1,α2)=2α1α2α1+α2,  α1,α2>0.

    3.The log-mean:

    L=L(α1,α2)=α2α1lnα2lnα1,   α1α2.

    4.The Generalized log-mean:

    Lr(α1,α2)=[αr+12αr+11(r+1)(α2α1)]1r;rR{1,0}.

    5.The Identric mean:

    I(α1,α2)={α1                    α1=α21e(αα22αα11)1α2α1        α1α2}.

    Dragomir et al. [21], have proved that for s(0,1), where 1r1s, the function φ(z)=zrs, z>0 is an s-convex function.

    Now, we present some applications to special means for positive real numbers using results of Section 5, as:

    Proposition 3. Let 0<α1<α2. Then for some fixed s[ln2.4,1), we obtain

    |Ars(α1,α2)Lrsrs(α1,α2)|(α2α1)K2n{ni=1(2+2(s1)ess22s2)i+ni=1(2ess22s22s2)i}. (6.1)

    Proof. The result holds by letting z=α1+α22 in Theorem 5.2 with n-polynomial exponentially s-convexity for φ:(0,)R, φ(z)=zrs, we obtain the required result.

    Proposition 4. Let 0<α1<α2 and q>1. Then for some fixed s[ln2.4,1), we obtain

    |lnI(α1,α2)lnA(α1,α2)|21q1Kqn(α2α1)(1p+1)1p{ni=1(ess1s)i}1q. (6.2)

    Proof. The result holds by letting z=α1+α22 in Theorem 5.2 with n-polynomial exponentially s-convexity for φ:(0,)R, φ(z)=lnz, we obtain the required result.

    Proposition 5. Let 0<α1<α2 and q1. Then for some fixed s[ln2.4,1), we obtain

    |H(α1,α2)L1(α1,α2)|(α2α1)qnK221q{ni=1(2+(2s2)ess22s2)i+ni=1(2ess22s22s2)i}1q. (6.3)

    Proof. The result holds by letting z=α1+α22 in Theorem 5.4 with n-polynomial exponentially s-convexity for φ:(0,)R, φ(z)=1z, we obtain the required result.

    In this paper, we have taken into consideration a critical extension of convexity, that is referred as n-polynomial exponentially s-convex functions and acquired new variants of Hermite-Hadamard inequality employing this new definition. We have also obtained refinements of the Ostrowski inequality for functions whose first derivatives in absolute value at certain power are n-polynomial exponential-type s-convex. Moreover, for different values of parameters, i.e., s,n and z, we have deduced some special cases of our main results. We presented some applications of our established results to special means of two positive real numbers. In the future, new inequalities for the other n- polynomial convex functions can be obtained by utilising the techniques used in this paper.

    The authors extend their appreciations to the Deanship of Post Graduate and Scientific Research at Dar Al Uloom University for funding this work.

    The authors declare that there are no conflicts of interest regarding the publication of this paper.



    Conflict of interest



    The authors declare no conflicts of interest.

    [1] Mitchell MJ, Billingsley MM, Haley RM, et al. (2021) Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 20: 101-124. https://doi.org/10.1038/s41573-020-0090-8
    [2] Prabhakar U, Maeda H, Jain RK, et al. (2013) Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Research 73: 2412-2417. https://doi.org/10.1158/0008-5472.CAN-12-4561
    [3] Zhang Y, Wang X (2020) Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol 13: 165. https://doi.org/10.1186/s13045-020-00990-3
    [4] Malone ER, Oliva M, Sabatini PJB, et al. (2020) Molecular profiling for precision cancer therapies. Genome Med 12: 8. https://doi.org/10.1186/s13073-019-0703-1
    [5] McGranahan N, Swanton C (2017) Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168: 613-628. https://doi.org/10.1016/j.cell.2017.01.018
    [6] Longo DL (2012) Tumor heterogeneity and personalized medicine. N Engl J Med 366: 956-957. https://doi.org/10.1056/NEJMe1200656
    [7] Adir O, Poley M, Chen G, et al. (2020) Integrating artificial intelligence and nanotechnology for precision cancer medicine. Adv Mater 32: e1901989. https://doi.org/10.1002/adma.201901989
    [8] Shamay Y, Shah J, Işık M, et al. (2018) Quantitative self-assembly prediction yields targeted nanomedicines. Nat Mater 17: 361-368. https://doi.org/10.1038/s41563-017-0007-z
    [9] Adir O, Poley M, Chen G, et al. (2019) Integrating artificial intelligence and nanotechnology for precision cancer medicine. Adv Mater 32: e1901989. https://doi.org/10.1002/adma.201901989
    [10] Al-Mohammedawi NA, Zaidan SA, Kashan JS (2024) Bioceramic scaffolds for bone repair and regeneration: a comprehensive review. J Appl Sci Nanotechnol 4: 39-57. https://doi.org/10.53293/jasn.2024.7223.1265
    [11] Rascio F, Spadaccino F, Rocchetti MT, et al. (2021) The pathogenic role of PI3K/AKT pathway in cancer onset and drug resistance: an updated review. Cancers 13: 3949. https://doi.org/10.3390/cancers13163949
    [12] Fazio M, Ablain J, Chuan Y, et al. (2020) Zebrafish patient avatars in cancer biology and precision cancer therapy. Nat Rev Cancer 20: 263-273. https://doi.org/10.1038/s41568-020-0252-3
    [13] de Jesus RA, Nascimento VRS, Costa JAS, et al. Empirical modeling, experimental optimization, and artificial intelligence (ANN-GA) as a tool for the efficient dye remediation by the biosilica extracted from sugarcane bagasse ash (2023). https://doi.org/10.1007/s13399-023-04825-2
    [14] Sun W, Chen G, Du F, et al. (2021) Targeted Drug Delivery to Cancer Stem Cells through Nanotechnological Approaches. Curr Stem Cell Re T 16: 367-384. https://doi.org/10.2174/1574888X15999201001204727
    [15] Lee JK, Liu Z, Sa JK, et al. (2018) Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nat Genet 50: 1399-1411. https://doi.org/10.1038/s41588-018-0209-6
    [16] Sadr S, Hajjafari A, Rahdar A, et al. (2024) Gold nanobiosensors and Machine Learning: Pioneering breakthroughs in precision breast cancer detection. Eur J Med Chem Rep 12: 100238. https://doi.org/10.1016/j.ejmcr.2024.100238
    [17] Fathi-karkan S, Shamsabadipour A, Moradi A, et al. (2024) Four-dimensional printing techniques: a comprehensive review of biomedical and tissue engineering developments. BioNanoSci 14: 4189-4218. https://doi.org/10.1007/s12668-024-01596-6
    [18] Hristova-Panusheva K, Xenodochidis C, Georgieva M, et al. (2024) Nanoparticle-mediated drug delivery systems for precision targeting in oncology. Pharmaceuticals 17: 677. https://doi.org/10.3390/ph17060677
    [19] Fu X, Shi Y, Qi T, et al. (2020) Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting. Sig Transduct Target Ther 5: 1-15. https://doi.org/10.1038/s41392-020-00342-0
    [20] Yao Y, Zhou Y, Liu L, et al. (2020) Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci 7: 193. https://doi.org/10.3389/fmolb.2020.00193
    [21] Siegel RL, Miller KD, Fuchs HE, et al. (2022) Cancer statistics, 2022. CA Cancer J Clin 72: 7-33. https://doi.org/10.3322/caac.21708
    [22] Wild CP (2019) The global cancer burden: necessity is the mother of prevention. Nat Rev Cancer 19: 123-124. https://doi.org/10.1038/s41568-019-0110-3
    [23] Elumalai K, Srinivasan S, Shanmugam A (2024) Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment. Biomed Technol 5: 109-122. https://doi.org/10.1016/j.bmt.2023.09.001
    [24] Mundekkad D, Cho WC (2022) Nanoparticles in clinical translation for cancer therapy. Int J Mol Sci 23: 1685. https://doi.org/10.3390/ijms23031685
    [25] Hu C-MJ, Aryal S, Zhang L (2010) Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv 1: 323-334. https://doi.org/10.4155/tde.10.13
    [26] Truong NP, Whittaker MR, Mak CW, et al. (2015) The importance of nanoparticle shape in cancer drug delivery. Expert Opin Drug Del 12: 129-142. https://doi.org/10.1517/17425247.2014.950564
    [27] Markman M (2006) Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary. Expert Opin Pharmacother 7: 1469-1474. https://doi.org/10.1517/14656566.7.11.1469
    [28] Hofheinz R-D, Gnad-Vogt SU, Beyer U, et al. (2005) Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 16: 691-707. https://doi.org/10.1097/01.cad.0000167902.53039.5a
    [29] Malam Y, Loizidou M, Seifalian AM (2009) Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 30: 592-599. https://doi.org/10.1016/j.tips.2009.08.004
    [30] Gubernator J (2011) Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity. Expert Opin Drug Deliv 8: 565-580. https://doi.org/10.1517/17425247.2011.566552
    [31] Pucci C, Martinelli C, Ciofani G (2019) Innovative approaches for cancer treatment: current perspectives and new challenges. ecancer 13: 961. https://doi.org/10.3332/ecancer.2019.961
    [32] Karapetis CS, Khambata-Ford S, Jonker DJ, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765. https://doi.org/10.1056/NEJMoa0804385
    [33] Di Nicolantonio F, Martini M, Molinari F, et al. (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705-5712. https://doi.org/10.1200/JCO.2008.18.0786
    [34] Gabizon AA, Patil Y, La-Beck NM (2016) New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. Drug Resist Update 29: 90-106. https://doi.org/10.1016/j.drup.2016.10.003
    [35] Gupta N, Hatoum H, Dy GK (2014) First line treatment of advanced non-small-cell lung cancer–specific focus on albumin bound paclitaxel. Int J Nanomed 9: 209-221. https://doi.org/10.2147/IJN.S41770
    [36] Passero FC, Grapsa D, Syrigos KN, et al. (2016) The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy. Expert Rev Anticanc 16: 697-703. https://doi.org/10.1080/14737140.2016.1192471
    [37] Kim M, Williams S (2018) Daunorubicin and cytarabine liposome in newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes. Ann Pharmacother 52: 792-800. https://doi.org/10.1177/1060028018764923
    [38] Raja A, Kasana A, Verma V, et al. Next-generation therapeutic antibodies for cancer treatment: advancements, applications, and challenges (2024). https://doi.org/10.1007/s12033-024-01270-y
    [39] Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, et al. (2024) CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Ther 31: 667-686. https://doi.org/10.1038/s41417-024-00750-2
    [40] Harrison TS, Lyseng-Williamson KA (2013) Vincristine sulfate liposome injection. BioDrugs 27: 69-74. https://doi.org/10.1007/s40259-012-0002-5
    [41] Yang L, Fang H, Jiang J, et al. (2022) EGFR-targeted pemetrexed therapy of malignant pleural mesothelioma. Drug Deliv Transl Res 12: 2527-2536. https://doi.org/10.1007/s13346-021-01094-2
    [42] Raskova Kafkova L, Mierzwicka JM, Chakraborty P, et al. NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy (2024). https://doi.org/10.3389/fimmu.2024.1342086
    [43] Sanchez C, Belleville P, Popall M, et al. (2011) Applications of advanced hybrid organic-inorganic nanomaterials: from laboratory to market. Chem Soc Rev 40: 696-753. https://doi.org/10.1039/c0cs00136h
    [44] Gao J, Chen K, Miao Z, et al. (2010) Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials 32: 2141. https://doi.org/10.1016/j.biomaterials.2010.11.053
    [45] Sun T, Zhang YS, Pang B, et al. (2014) Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Engl 53: 12320-12364. https://doi.org/10.1002/anie.201403036
    [46] Kim EM, Jeong HJ (2017) Current status and future direction of nanomedicine: focus on advanced biological and medical applications. Nucl Med Mol Imaging 51: 106-117. https://doi.org/10.1007/s13139-016-0435-8
    [47] Vijaya Lakshmi K (2023) Artificial intelligence and its applications in nanochemistry. IJETMS 7: 385-389. https://doi.org/10.46647/ijetms.2023.v07i05.046
    [48] Zhu X, Li Y, Gu N (2023) Application of artificial intelligence in the exploration and optimization of biomedical nanomaterials. Nano Biomed Eng 15: 342-353. https://doi.org/10.26599/NBE.2023.9290035
    [49] Serrano DR, Luciano FC, Anaya BJ, et al. (2024) Artificial intelligence (AI) applications in drug discovery and drug delivery: revolutionizing personalized medicine. Pharmaceutics 16: 1328. https://doi.org/10.3390/pharmaceutics16101328
    [50] Chan EM, Xu C, Mao AW, et al. (2010) Reproducible, high-throughput synthesis of colloidal nanocrystals for optimization in multidimensional parameter space. Nano Lett 10: 1874-1885. https://doi.org/10.1021/nl100669s
    [51] Kajita S, Ohba N, Suzumura A, et al. (2020) Discovery of superionic conductors by ensemble-scope descriptor. NPG Asia Mater 12: 1-8. https://doi.org/10.1038/s41427-020-0211-1
    [52] Yamankurt G, Berns EJ, Xue A, et al. (2019) Exploration of the nanomedicine-design space with high-throughput screening and machine learning. Nat Biomed Eng 3: 318-327. https://doi.org/10.1038/s41551-019-0351-1
    [53] Yuan M, Kermanian M, Agarwal T, et al. (2023) Defect engineering in biomedical sciences. Adv Mater 35: 2304176. https://doi.org/10.1002/adma.202304176
    [54] Wu Y, Duan H, Xi H (2020) Machine learning-driven insights into defects of zirconium metal–organic frameworks for enhanced ethane–ethylene separation. Chem Mater 32: 2986-2997. https://doi.org/10.1021/acs.chemmater.9b05322
    [55] Li S, Barnard AS (2022) Inverse design of nanoparticles using multi-target machine learning. Adv Theor Simul 5: 2100414. https://doi.org/10.1002/adts.202100414
    [56] Thomas DG, Chikkagoudar S, Heredia-Langner A, et al. (2014) Physicochemical signatures of nanoparticle-dependent complement activation. Comput Sci Discov 7: 015003. https://doi.org/10.1088/1749-4699/7/1/015003
    [57] Boso DP, Lee S-Y, Ferrari M, et al. (2011) Optimizing particle size for targeting diseased microvasculature: from experiments to artificial neural networks. IJN 6: 1517-1526. https://doi.org/10.2147/IJN.S20283
    [58] Galasso I, Erikainen S, Pickersgill M, et al. (2024) “Different names for the same thing”? novelty, expectations, and performative nominalism in personalized and precision medicine. Soc Theory Health 22: 139-155. https://doi.org/10.1057/s41285-024-00203-8
    [59] Schleidgen S, Klingler C, Bertram T, et al. (2013) What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics 14: 55. https://doi.org/10.1186/1472-6939-14-55
    [60] Delpierre C, Lefèvre T (2023) Precision and personalized medicine: What their current definition says and silences about the model of health they promote. Implication for the development of personalized health. Front Sociol 8: 1112159. https://doi.org/10.3389/fsoc.2023.1112159
    [61] Das KP, J C (2023) Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: current progress and challenges. Front Med Technol 4: 1067144. https://doi.org/10.3389/fmedt.2022.1067144
    [62] Wang J, Liu G, Zhou C, et al. (2024) Application of artificial intelligence in cancer diagnosis and tumor nanomedicine. Nanoscale 16: 14213-14246. https://doi.org/10.1039/D4NR01832J
    [63] Majumder J, Taratula O, Minko T (2019) Nanocarrier-based systems for targeted and site specific therapeutic delivery. Adv Drug Deliver Rev 144: 57. https://doi.org/10.1016/j.addr.2019.07.010
    [64] Yook S, Cai Z, Lu Y, et al. (2015) Radiation nanomedicine for EGFR-positive breast cancer: panitumumab-modified gold nanoparticles complexed to the β-particle-emitter, (177)Lu. Mol Pharm 12: 3963-3972. https://doi.org/10.1021/acs.molpharmaceut.5b00425
    [65] Sharkey RM, Goldenberg DM (2006) Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 56: 226-243. https://doi.org/10.3322/canjclin.56.4.226
    [66] Adir O, Poley M, Chen G, et al. (2019) Integrating artificial intelligence and nanotechnology for precision cancer medicine. Adv Mater 32: e1901989. https://doi.org/10.1002/adma.201901989
    [67] Ori MO, Ekpan FM, Samuel HS, et al. (2024) Integration of artificial intelligence in nanomedicine. Eurasian J Sci Technol 4: 88-104. https://doi.org/10.48309/EJST.2024.422419.1105
    [68] Medhi B, Sharma DH, Kaundal DT, et al. (2024) Artificial intelligence: a catalyst for breakthroughs in nanotechnology and pharmaceutical research. IJPSN 17: 7439-7445. https://doi.org/10.37285/ijpsn.2024.17.4.1
    [69] Gawel AM, Betkowska A, Gajda E, et al. (2024) Current non-metal nanoparticle-based therapeutic approaches for glioblastoma treatment. Biomedicines 12: 1822. https://doi.org/10.3390/biomedicines12081822
    [70] Qi G, Shi G, Wang S, et al. (2023) A novel pH-responsive Iron oxide core-shell magnetic mesoporous Silica nanoparticle (M-MSN) system encapsulating doxorubicin (DOX) and glucose oxidase (Gox) for pancreatic cancer treatment. Int J Nanomed 18: 7133-7147. https://doi.org/10.2147/IJN.S436253
    [71] Choi KY, Liu G, Lee S, et al. (2012) Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nanoscale 4: 330-342. https://doi.org/10.1039/C1NR11277E
    [72] Ristau BT, O'Keefe DS, Bacich DJ (2014) The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol Oncol 32: 272-279. https://doi.org/10.1016/j.urolonc.2013.09.003
    [73] Ciccarese C, Bauckneht M, Zagaria L, et al. (2024) Defining the position of [177Lu] Lu-PSMA radioligand therapy in the treatment landscape of metastatic castration-resistant prostate cancer: a meta-analysis of clinical trials. Targ Oncol 2024: 1-10. https://doi.org/10.1007/s11523-024-01117-1
    [74] Von Hoff DD, Mita MM, Ramanathan RK, et al. (2016) Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors. Clin Cancer Res 22: 3157-3163. https://doi.org/10.1158/1078-0432.CCR-15-2548
    [75] Ni J, Miao T, Su M, et al. (2021) PSMA-targeted nanoparticles for specific penetration of blood-brain tumor barrier and combined therapy of brain metastases. J Control Release 329: 934-947. https://doi.org/10.1016/j.jconrel.2020.10.023
    [76] Autio KA, Garcia JA, Alva AS, et al. (2016) A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). JCO 34: 233-233. https://doi.org/10.1200/jco.2016.34.2_suppl.233
    [77] Bakht MK, Beltran H (2024) Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat Rev Urol 2024: 1-20. https://doi.org/10.1038/s41585-024-00900-z
    [78] Zahednezhad F, Allahyari S, Sarfraz M, et al. (2024) Liposomal drug delivery systems for organ-specific cancer targeting: early promises, subsequent problems, and recent breakthroughs. Expert Opinion Drug Del 21: 1363-1384. https://doi.org/10.1080/17425247.2024.2394611
    [79] Rizwanullah M, Ahmad MZ, Ghoneim MM, et al. (2021) Receptor-mediated targeted delivery of surface-modifiednanomedicine in breast cancer: recent update and challenges. Pharmaceutics 13: 2039. https://doi.org/10.3390/pharmaceutics13122039
    [80] Guddo F, Giatromanolaki A, Koukourakis MI, et al. (1998) MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol 51: 667-671. https://doi.org/10.1136/jcp.51.9.667
    [81] Wurz GT, Kao CJ, Wolf M, et al. (2014) Tecemotide: an antigen-specific cancer immunotherapy. Hum Vacc Immunother 10: 3383-3393. https://doi.org/10.4161/hv.29836
    [82] Cats A, Jansen EPM, Grieken NCT van, et al. (2018) Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol 19: 616-628. https://doi.org/10.1016/S1470-2045(18)30132-3
    [83] Sabir F, Qindeel M, Zeeshan M, et al. (2021) Onco-receptors targeting in lung cancer via application of surface-modified and hybrid nanoparticles: a cross-disciplinary review. Processes 9: 621. https://doi.org/10.3390/pr9040621
    [84] Hoshyar N, Gray S, Han H, et al. (2016) The effect of nanoparticle size on In Vivo pharmacokinetics and cellular interaction. Nanomedicine (Lond) 11: 673-692. https://doi.org/10.2217/nnm.16.5
    [85] Zrazhevskiy P, Sena M, Gao X (2010) Designing multifunctional quantum dots for bioimaging, detection, and drug delivery. Chem Soc Rev 39: 4326. https://doi.org/10.1039/b915139g
    [86] Singh P, Pandit S, Mokkapati VRSS, et al. (2018) Gold nanoparticles in diagnostics and therapeutics for human cancer. IJMS 19: 1979. https://doi.org/10.3390/ijms19071979
    [87] Kim D, Jeong YY, Jon S (2010) A drug-loaded aptamer–gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano 4: 3689-3696. https://doi.org/10.1021/nn901877h
    [88] Wilson K, Homan K, Emelianov S (2012) Biomedical photoacoustics beyond thermal expansion using triggered nanodroplet vaporization for contrast-enhanced imaging. Nat Commun 3: 618. https://doi.org/10.1038/ncomms1627
    [89] Dias R, Torkamani A (2019) Artificial intelligence in clinical and genomic diagnostics. Genome Med 11: 70. https://doi.org/10.1186/s13073-019-0689-8
    [90] Aung KL, Fischer SE, Denroche RE, et al. (2018) Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin Cancer Res 24: 1344-1354. https://doi.org/10.1158/1078-0432.CCR-17-2994
    [91] Rao W, Wang H, Han J, et al. (2015) Chitosan-decorated doxorubicin-encapsulated nanoparticle targets and eliminates tumor reinitiating cancer stem-like cells. ACS Nano 9: 5725-5740. https://doi.org/10.1021/nn506928p
    [92] Senapati S, Mahanta AK, Kumar S, et al. (2018) Controlled drug delivery vehicles for cancer treatment and their performance. Sig Transduct Target Ther 3: 7. https://doi.org/10.1038/s41392-017-0004-3
    [93] Xu Y, Hosny A, Zeleznik R, et al. (2019) Deep learning predicts lung cancer treatment response from serial medical imaging. Clin Cancer Res 25: 3266-3275. https://doi.org/10.1158/1078-0432.CCR-18-2495
    [94] Sun Z, Song C, Wang C, et al. (2020) Hydrogel-based controlled drug delivery for cancer treatment: a review. Mol Pharmaceutics 17: 373-391. https://doi.org/10.1021/acs.molpharmaceut.9b01020
    [95] Sykes EA, Dai Q, Sarsons CD, et al. (2016) Tailoring nanoparticle designs to target cancer based on tumor pathophysiology. Proc Natl Acad Sci USA 113: E1142-E1151. https://doi.org/10.1073/pnas.1521265113
    [96] Bhinder B, Gilvary C, Madhukar NS, et al. (2021) Artificial intelligence in cancer research and precision medicine. Cancer Discov 11: 900-915. https://doi.org/10.1158/2159-8290.CD-21-0090
    [97] Zhang Y, Lin R, Li H, et al. (2019) Strategies to improve tumor penetration of nanomedicines through nanoparticle design. WIREs Nanomed Nanobiotechnol 11: e1519. https://doi.org/10.1002/wnan.1519
    [98] Keith JA, Vassilev-Galindo V, Cheng B, et al. (2021) Combining machine learning and computational chemistry for predictive insights into chemical systems. Chem Rev 121: 9816-9872. https://doi.org/10.1021/acs.chemrev.1c00107
    [99] Kennedy LC, Bickford LR, Lewinski NA, et al. (2011) A new era for cancer treatment: gold-nanoparticle-mediated thermal therapies. Small 7: 169-183. https://doi.org/10.1002/smll.201000134
    [100] Merino S, Martín C, Kostarelos K, et al. (2015) Nanocomposite hydrogels: 3D polymer–nanoparticle synergies for on-demand drug delivery. ACS Nano 9: 4686-4697. https://doi.org/10.1021/acsnano.5b01433
    [101] Fröhlich E (2012) The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. IJN 2012: 5577-5591. https://doi.org/10.2147/IJN.S36111
    [102] AI FORM: An AI-Driven Platform for Acceleration of Nanomedicine Development Science Foundation Ireland. Available from: https://www.sfi.ie/challenges/future-digital/ai-form/
    [103] The Power of AI-Generated Nanoparticles in Targeted Drug DeliveryNano Magazine - Latest Nanotechnology News (2023). Available from: https://nano-magazine.com/news/2023/7/3/the-power-of-ai-generated-nanoparticles-in-targeted-drug-delivery
    [104] Greenberg ZF, Graim KS, He M (2023) Towards artificial intelligence-enabled extracellular vesicle precision drug delivery. Adv Drug Deliver Rev 199: 114974. https://doi.org/10.1016/j.addr.2023.114974
    [105] Weerarathna IN, Kamble AR, Luharia A (2023) Artificial intelligence applications for biomedical cancer research: a review. Cureus 15: e48307. https://doi.org/10.7759/cureus.48307
    [106] Chugh V, Basu A, Kaushik A, et al. (2024) Employing nano-enabled artificial intelligence (AI)-based smart technologies for prediction, screening, and detection of cancer. Nanoscale 16: 5458-5486. https://doi.org/10.1039/D3NR05648A
    [107] Liu J, Du H, Huang L, et al. (2024) AI-powered microfluidics: shaping the future of phenotypic drug discovery. ACS Appl Mater Interfaces 16: 38832-38851. https://doi.org/10.1021/acsami.4c07665
  • This article has been cited by:

    1. Muhammad Bilal Riaz, Aziz Ur Rehman, Jan Awrejcewicz, Fahd Jarad, Double Diffusive Magneto-Free-Convection Flow of Oldroyd-B Fluid over a Vertical Plate with Heat and Mass Flux, 2022, 14, 2073-8994, 209, 10.3390/sym14020209
    2. Rozana Liko, Hari Mohan Srivastava, Pshtiwan Othman Mohammed, Artion Kashuri, Eman Al-Sarairah, Soubhagya Kumar Sahoo, Mohamed S. Soliman, Parameterized Quantum Fractional Integral Inequalities Defined by Using n-Polynomial Convex Functions, 2022, 11, 2075-1680, 727, 10.3390/axioms11120727
    3. Muhammad Bilal Khan, Hatim Ghazi Zaini, Jorge E. Macías-Díaz, Savin Treanțǎ, Mohamed S. Soliman, Some Fuzzy Riemann–Liouville Fractional Integral Inequalities for Preinvex Fuzzy Interval-Valued Functions, 2022, 14, 2073-8994, 313, 10.3390/sym14020313
    4. Muhammad Samraiz, Kanwal Saeed, Saima Naheed, Gauhar Rahman, Kamsing Nonlaopon, On inequalities of Hermite-Hadamard type via $ n $-polynomial exponential type $ s $-convex functions, 2022, 7, 2473-6988, 14282, 10.3934/math.2022787
    5. Mohammad Younus Bhat, Badr Alnssyan, Aamir H. Dar, Javid G. Dar, Sampling Techniques and Error Estimation for Linear Canonical S Transform Using MRA Approach, 2022, 14, 2073-8994, 1416, 10.3390/sym14071416
    6. Jarunee Soontharanon, Muhammad Aamir Ali, Hüseyin Budak, Pinar Kösem, Kamsing Nonlaopon, Thanin Sitthiwirattham, Behrouz Parsa Moghaddam, Some New Generalized Fractional Newton’s Type Inequalities for Convex Functions, 2022, 2022, 2314-8888, 1, 10.1155/2022/6261970
    7. Bakhtiar Ahmad, Wali Khan Mashwani, Serkan Araci, Saima Mustafa, Muhammad Ghaffar Khan, Bilal Khan, A subclass of meromorphic Janowski-type multivalent q-starlike functions involving a q-differential operator, 2022, 2022, 2731-4235, 10.1186/s13662-022-03683-y
    8. Muhammad Tariq, Omar Mutab Alsalami, Asif Ali Shaikh, Kamsing Nonlaopon, Sotiris K. Ntouyas, New Fractional Integral Inequalities Pertaining to Caputo–Fabrizio and Generalized Riemann–Liouville Fractional Integral Operators, 2022, 11, 2075-1680, 618, 10.3390/axioms11110618
    9. LEI XU, SHUHONG YU, TINGSONG DU, PROPERTIES AND INTEGRAL INEQUALITIES ARISING FROM THE GENERALIZED n-POLYNOMIAL CONVEXITY IN THE FRAME OF FRACTAL SPACE, 2022, 30, 0218-348X, 10.1142/S0218348X22500840
    10. Asif Ali Shaikh, Evren Hincal, Sotiris K. Ntouyas, Jessada Tariboon, Muhammad Tariq, Some Hadamard-Type Integral Inequalities Involving Modified Harmonic Exponential Type Convexity, 2023, 12, 2075-1680, 454, 10.3390/axioms12050454
    11. Muhammad Tariq, Sotiris K. Ntouyas, Bashir Ahmad, Ostrowski-Type Fractional Integral Inequalities: A Survey, 2023, 3, 2673-9321, 660, 10.3390/foundations3040040
  • Reader Comments
  • © 2024 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(1683) PDF downloads(87) Cited by(0)

Figures and Tables

Figures(4)  /  Tables(2)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog